However, owing to the recent successes of a new generation of 177Lu-based RPTs, namely peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumours and prostate-specific membrane antigen radioligand therapy (PSMA-RLT) of prostate cancer, the field of theranostics is now developing at an accelerated pace and transforming the practice of nuclear medicine [1–3]. The gene discussed is FOLH1; the disease is neuroendocrine neoplasm.